NCT02122744

Brief Summary

Evaluation of inhibiting rTMS QP over the visual cortex for the prevention of chronic migraine. The aim of the study is to confirm that inhibiting rTMS QP is capable to decrease the frequency of migraine and if its effect is stronger than placebo effect.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2013

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2013

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

November 4, 2013

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2014

Completed
24 days until next milestone

First Posted

Study publicly available on registry

April 25, 2014

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2014

Completed
Last Updated

August 18, 2020

Status Verified

August 1, 2020

Enrollment Period

7 months

First QC Date

November 4, 2013

Last Update Submit

August 15, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Frequency of migraine

    The investigators evaluate the frequency of migraine during the treatment and 2 months after its end.

    12 months

Secondary Outcomes (4)

  • Intensity of migraine

    12 months

  • Acute medication intake

    12 months

  • Attack duration

    12 months

  • Scores on psychological scales

    12 months

Study Arms (2)

Super Rapid Magstim Stimulator rTMS QP

ACTIVE COMPARATOR

rTMS QP is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients

Device: Super Rapid Magstim Stimulator

Placebo

PLACEBO COMPARATOR

rTMS QP placebo (coil perpendicular to the scalp) is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients.

Device: Super Rapid Magstim Stimulator (sham)

Interventions

The repetitive transcranial magnetic stimulation (rTMS) is able to modify cortical excitability and reactivity. 1Hz rTMS inhibits the cortex, 10Hz excites it. In particular, a new paradigm of rTMS, the rTMS quadri pulse has a more lasting and effective activity. The side effects are rare and transient: migraine,contractions of the muscles of the neck due to muscle stimulation by the electromagnetic field of the coil.

Super Rapid Magstim Stimulator rTMS QP

coil perpendicular to the scalp

Placebo

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • diagnosis of chronic migraine (ICHD III beta 1.3) with or without medication overuse.

You may not qualify if:

  • other diseases or contraindication for the magnetic stimulation (epilepsy, pacemaker, metallic prothesis)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Roberta Baschi

Liège, 4000, Belgium

Location

Study Officials

  • Jean Schoenen, HP

    University of Liege

    PRINCIPAL INVESTIGATOR
  • Delphine Magis, MD,PhD

    University of Liege

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Honorary Full Professor

Study Record Dates

First Submitted

November 4, 2013

First Posted

April 25, 2014

Study Start

September 1, 2013

Primary Completion

April 1, 2014

Study Completion

September 1, 2014

Last Updated

August 18, 2020

Record last verified: 2020-08

Locations